On August 9, 2012, Lankau, Hans-Joachim; Langen, Barbara; Grunwald, Christian; Hoefgen, Norbert; Stange, Hans; Dost, Rita; Egerland, Ute published a patent.Recommanded Product: 62163-09-1 The title of the patent was Preparation of (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases for treating CNS disorders and other diseases. And the patent contained the following:
The invention relates to (1,2,4)triazolo[4,3-a]quinoxaline derivatives of Formula I (wherein R1 is Ph, 2-pyridyl, 3-pyridyl or 4-pyridyl, all optionally substituted; R2 is H or (un)substituted C1-4 alkyl; R3, R4, R5 and R6 are independently H, halo, (un)substituted C1-4 alkyl, etc.) that are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases. Synthetic procedures for preparing I are exemplified. Example compound II was prepared in a 5-step synthesis that culminates in cyclization of intermediate 2-chlorobenzoic acid N’-(7-chloro-3-methylquinoxalin-2-yl)hydrazide. In assays measuring inhibition of recombinant PDE10A and PDE2A (expressed in baculovirus/SF21 cells), II had IC50 values of 0.045 and 0.003 μM, resp. The experimental process involved the reaction of 5-Chloroquinoxaline(cas: 62163-09-1).Recommanded Product: 62163-09-1
The Article related to triazoloquinoxaline derivative preparation inhibitor phosphodiesterase treatment cns disorder, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: 62163-09-1
Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider